Device design considerations. Our device was designed to be completely free-standing and provide both recording and stimulation of tissue function, as well as allow spatial release of biochemical factors. The whole fabrication process was accomplished on a nickel sacrificial layer that was removed as the last stage of processing. This yields a completely free-standing, flexible device. To achieve high porosity (>99%) and minimally interfere with tissue formation, pore sizes were ~100 x 1,300 μm 2 . SU-8 was chosen both as the substrate and passivation material due to its ease of processing, relative flexibility and transparency which can be later exploited for fluorescent imaging assays. SU-8 passivation allowed electrode exposure only at the terminating pads, which were designed for either recording/stimulating or drug release. Recording/stimulating electrodes were small enough (50x50 μm 2 ) to enable recording from specific regions within the tissue but not too small so as impedance and thermal noise might interfere with the quality of recording. The entire device included 28 recording/stimulating pads dispersed throughout the long dimension of the device in pairs with distances ranging between 600 and 1500 μm, while 4 larger pads (150x150 μm 2 ) were designed to accommodate controlled release systems. These large electrodes were placed at equal distances (~4,500 µm) along the device to allow spatially controlled drug release throughout the tissue. Electrode pad size was designed to limit contact to as few cells as possible while avoiding impedance limitations that might occur with smaller electrode sizes.
Electrochemical impedance spectroscopy measured in phosphate buffered saline showed an impedance of ~0.1 kΩ at a frequency of 1 kHz ( Supplementary Fig S20) . Larger electrode pad sizes were designed to allow bulk electroactive polymer deposition for drug release. Two large grounding electrodes were placed on each side of the device to serve as counter electrodes for stimulation purposes. A rough nanoscale layer of titanium nitride (TiN) was deposited on the gold pads to increase their surface area. The electronic network was designed to be flexible to enable rolling or folding together with the biomaterial scaffold to create a thick 3D structure. Thus, distant electrodes within the electronics are re-organized in space to form a denser electrode network and enable 3D monitoring of tissue function. Overall, the dimensions of the electronic chip were ~20 mm x ~5 mm to enable engineering of thick tissues.
Detailed device fabrication. Free-standing devices were fabricated on the oxide surface of silicon substrates (University wafer, Boston, MA) prior to relief from the substrate. Key steps used in the fabrication process ( Figure S1 ) were as follows: 1) Thin layer metal deposition was performed Figure S1f ). The devices did not adhere to the substrate and floated in the liquid, after which they were transferred to water to wash any remnants of acid and dried in air before use. Ag/AgCl ink (ALS, Tokyo, Japan) was used for reference electrodes. The device and its components were biocompatible as shown in Supplementary Fig. S21 .
SEM.
Samples were mounted onto aluminum stubs with conductive paint and sputter-coated with an ultrathin (150Å) layer of gold in a Polaron E 5100 coating apparatus (Quorum technologies, Laughton, UK). The samples were viewed under JSM-840A SEM (JEOL, Tokyo, Japan). Images of higher resolution were obtained using a JSM-6700F SEM (JEOL).
Metallurgical Confocal microscopy. Confocal and metallurgical microscopy images of the electrodes were taken using an Olympus LEXT 4000 confocal microscope (OLYMPUS, Tokyo, Japan).
Atomic force microscopy. Topography measurements were performed by atomic force microscopy (AFM, Molecular imaging Pico Plus, Agilent, Santa Clara, CA) with the use of PicoScan5 software. Scanning was performed on whole devices on wafers.
Electrical resistance measurements. All measurements of conductivity were performed using a Keithley 4200 Semiconductor characterization system (Keithley Instruments, Cleveland, OH) using a two probe set up. Resistance was measured by scanning current as a function of voltage change and extrapolating the resistance. Perturbations were performed and measurements taken before and after and conductivity was compared.
Protein release from chondroitin sulfate. Three hundred mg chondroitin 4-sulfate (CS) (SigmaAldrich) were dissolved in 1.14 ml of 1 N NaOH under vigorous stirring. Two hundred and forty μL of the cross-linker EGDGE (Sigma-Aldrich) were then added and mixed thoroughly. The mixture was degassed under vacuum for 10 min, after which it was transferred to a mold. The latter was sealed and placed in an oven at 60°C for 60 min. Cross-linking of the polymer took place and a gel was formed. After cooling at room temperature, the cylindrical hydrogel was removed from the mold, cut into small slices, washed in double distilled water in glass vials, and left in 4°C for 3 days to obtain equilibrium swelling. The water was replaced daily. Washing was carried out to remove any un-reacted polymer/cross-linker from the gel. All release experiments were conducted at room temperature in PBS, using a custom-made release chamber. The gels were then placed in a solution of lysozyme in double distilled water for 24 hours. One piece of protein loaded gel was removed from the loading medium, blotted dry, rinsed with a PBS buffer, blotted dry once again, and then placed on the device under a binocular. Electrical stimulation (1 V, 10 min on, 20 min off) was applied by creating an electric field between the electrode on to which the gel was placed and one of the ground electrodes. Protein release was followed by taking samples of the medium every 30 min. The samples were replaced by adding an equal volume of buffer to the release chamber. The passive release experiments were conducted in the same way without stimulation.
Lysozyme release was quantified by absorbance at 280 nm using a NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop, Wilmington, DE) S1 . Release was performed using a fully fabricated microECP (n≥3).
Protein loading analysis. Protein loading was measured by placing cylindrical hydrogels of the same size in a 1 mL protein solution. Both lysozyme and SDF-1 solutions were used with varying concentrations. Protein concentration was measured at the beginning of the experiment and every 24 hours. Protein concentration was assessed by ELISA for SDF-1 and spectrophotometry at 280 nm for lysozyme.
SDF-1 loading and release. SDF-1 was loaded and released in the same manner as lysozyme.
SDF-1 was detected using a human CXCL12/SDF-1 ELISA kit (R&D systems, Minneapolis, MN). Fiber Diameter analysis. Images of fibers were taken using a SEM as described before and fiber diameter analyzed using ImageJ software (NIH).
Cardiac cell isolation, seeding and cultivation. Cardiac cells were isolated according to Tel Aviv
University ethical use protocols as previously described S3 . Briefly, left ventricles of 0-3-day-old neonatal Sprague-Dawley rats (Harlan Laboratories, Israel) were harvested, and cells were isolated using six cycles (30 min each at 37 o C) of enzyme digestion with collagenase type II (95 U/mL; Worthington, Lakewood, NJ) and pancreatin (0.6 mg/mL; Sigma-Aldrich) in Dulbecco's modified Eagle Medium (DMEM, CaCl2·2H20 (1.8 mM), KCl (5.36 mM), MgSO4·7H2O (0.81 mM), NaCl (0.1 M), NaHCO3 (0.44 mM), NaH2PO4 (0.9 mM)). After each round of digestion cells were centrifuged (600G, 5 min) and resuspended in culture medium composed of M-199 supplemented with 0.6mM CuSO45·H2O, 0.5mM ZnSO4·7H2O, 1.5mM vitamin B12, 500 U/mL Penicillin and 100 mg/mL streptomycin, and 0.5% (v/v) FBS. To enrich the cardiomyocytes population, cells were suspended in culture medium with 5% FBS and pre-plated twice (45 min).
Cell number and viability were determined by a hemocytometer and trypan blue exclusion assay.
Prior to cell seeding the devices were incubated in a solution of 10 μg/ml of fibronectin (Biological Industries, Kibbutz Beit-Haemek, Israel) in PBS for 24 h in order to improve cell adhesion to the device.
Two million cardiac cells were seeded onto the devices by adding 30 μL of the suspended cells followed by a 1 h incubation period (37 0 C, 5% CO2). Cells were suspended in 50% culture medium and 50% Matrigel (Corning Life Sciences, Tewksbury, MA). Following, cell constructs were supplemented with culture medium (5% FBS) and further incubated.
Immunostaining. Immunostaining was performed as previously described S3 . Cardiac cell constructs were fixed and permeabilized in 100% cold methanol for 10 min, washed three times in DMEM-based buffer and then blocked for 1 h at room temperature in DMEM-based buffer containing 2% FBS, after which the samples were washed three times. The samples were then
